Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report.
Holman, Laura L; Ren, Yulan; Westin, Shannon N.
; 15: 728, 2015 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-26474752
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
Improved survival with bevacizumab in advanced cervical cancer.
Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer.
Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.